

## Original Article

## Non-Tuberculous Mycobacteria. An Emerging Threat? ☆



Susana Martínez González,<sup>a,\*</sup> Arantza Cano Cortés,<sup>b</sup> Luis Alfonso Sota Yoldi,<sup>c</sup> José María García García,<sup>d</sup> Luz María Alba Álvarez,<sup>a</sup> Juan José Palacios Gutiérrez<sup>a</sup>, en representación de la Red de Laboratorios de Microbiología del SESPA ◇

<sup>a</sup> Unidad de Referencia Regional de Micobacterias, Servicio de Microbiología, AGC Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

<sup>b</sup> Servicio de Neumología, Hospital Santa Marina, Bilbao, Bizkaia, Spain

<sup>c</sup> Servicio de Neumología, Fundación Hospital de Jove, Gijón, Asturias, Spain

<sup>d</sup> Unidad de Gestión Clínica de Neumología, Hospital San Agustín, Avilés, Asturias, Spain

## ARTICLE INFO

## Article history:

Received 28 October 2016

Accepted 27 February 2017

Available online 31 August 2017

## Keywords:

Non-tuberculous mycobacteria  
Non-tuberculous mycobacteria infection  
Mycobacteriosis  
*Mycobacterium kansasii*  
*Mycobacterium avium* complex

## ABSTRACT

**Introduction and objective:** Non-tuberculous mycobacteria (NTM) isolates are becoming more common. The main objective of our study was to establish the number and diversity of NTM species in our region and their distribution according to the source sample, age and gender of the patients, and to analyze clinically significant isolates.

**Methodology:** Prospective study of all NTM isolated in Asturias from 2005 to 2012. Samples were processed following internationally accepted guidelines. Statistical analysis was based on Fisher's exact test for 2×2 contingency tables.

**Results:** A total of 3284 mycobacteria were isolated: 1499 *Mycobacterium tuberculosis* complex (MTB) and 1785 NTM. During the study, NTM isolation rates increased while MTB isolation decreased. NTM were more frequent in men ( $p<0.001$ ). *M. gordonae* was the most frequently isolated species but did not cause disease in any case. NTM isolates from 212 patients were associated with clinically significant disease (17.1%). *M. kansasii* and *M. avium* were most commonly associated with disease. The number of *M. kansasii* isolates from men was statistically significant ( $p<0.01$ ).

**Conclusions:** In our study, NTM isolates increased by 35%, compared with a 21% decline in cases of MTB. Both isolation of NTM and clinically significant cases were more common in men. Only 17.1% of NTM isolates were associated with disease, most commonly *M. avium* complex and *M. kansasii*.

© 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

## Micobacterias no tuberculosas. ¿Una amenaza emergente?

## RESUMEN

**Introducción y objetivo:** Los aislamientos de micobacterias no tuberculosas (MNT) son cada vez más frecuentes. El objetivo principal de nuestro estudio fue conocer el número y la variedad de especies de MNT en nuestra región, su distribución según el origen de la muestra, y la edad y sexo de los pacientes; asimismo, analizar pormenorizadamente los aislamientos clínicamente significativos.

**Metodología:** Estudio prospectivo que incluye todas las MNT aisladas en Asturias durante el período 2005–2012. Las muestras se procesaron siguiendo directrices internacionalmente aceptadas. Para el tratamiento estadístico de los datos se utilizaron tablas de contingencia 2×2 aplicando el test exacto de Fisher.

## Palabras clave:

Micobacterias no tuberculosas  
Infecciones por *Mycobacterium*  
Mycobacteriosis  
*Mycobacterium kansasii*  
*Mycobacterium avium* complex

☆ Please cite this article as: Martínez González S, Cano Cortés A, Sota Yoldi LA, García García JM, Alba Álvarez LM, Palacios Gutiérrez JJ, et al. Micobacterias no tuberculosas. ¿Una amenaza emergente? Arch Broncopneumol. 2017;53:554–560.

\* Corresponding author.

E-mail address: [susanamargon@yahoo.es](mailto:susanamargon@yahoo.es) (S. Martínez González).

◇ La Red de Laboratorios de Microbiología del SESPA incluye los Servicios de Microbiología de: Hospital de Jarrio, Hospital Carmen y Severo Ochoa, Hospital San Agustín, Hospital de Cabueñes, Hospital de Jove, Hospital Grande Covián, Hospital Álvarez-Buylla, Hospital Valle del Nalón y Hospital Universitario Central de Asturias (HUCA).

**Resultados:** Se aislaron 3.284 micobacterias: 1.499 *Mycobacterium tuberculosis* complex (MTB) y 1.785 MNT. A lo largo del estudio se incrementaron los aislamientos de MNT y se redujeron los de MTB. Los aislamientos de MNT fueron más numerosos en hombres que en mujeres ( $P < 0,001$ ). *M. gordonae*, la especie más frecuentemente aislada, no originó enfermedad en ningún caso. El aislamiento fue clínicamente significativo en 212 pacientes (17,1%), siendo *M. kansasii* y *M. avium* las especies que más frecuentemente causaron enfermedad. La diferencia de aislamientos de *M. kansasii* entre mujeres y hombres fue estadísticamente significativa ( $p < 0,01$ ).

**Conclusiones:** En nuestro estudio, los aislamientos de MNT se incrementaron un 35%, frente a un descenso del 21% de los casos de MTB. Tanto los aislamientos de MNT como los casos clínicamente significativos fueron más frecuentes en hombres. Solo un 17,1% de las MNT aisladas, principalmente *M. avium* complex (MAC) y *M. kansasii*, ocasionaron enfermedad.

© 2017 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

## Introduction

Non-tuberculous mycobacteria (NTM) have gained prominence in recent years, and now account for between 30% and 50% of the total number of mycobacteria isolated in microbiology laboratories<sup>1</sup>; this phenomenon may be associated with an increased incidence of disease caused by NTM. The reasons for this increase are not entirely clear. The introduction of automated liquid culture systems in mycobacteria laboratories in the 1990s may have played a decisive role in improving diagnostic yield,<sup>2–4</sup> although in their first decade of continued use no such dramatic increase in NTM isolation rates was reported.<sup>5–15</sup> In general, data on the incidence and prevalence of NTM are scant<sup>2</sup> and probably determined by the ability of each laboratory to isolate these organisms and the available diagnostic tools.

More than 170 species of mycobacteria have been described to date (<http://www.bacterio.cict.fr/m/mycobacterium.html>).

The most frequently isolated species are *Mycobacterium avium* complex (MAC), *M. gordonae*, *M. kansasii*, *M. marinum*, *M. xenopi*, *M. fortuitum*, *M. chelonae* and *M. abscessus*.

Generally, most isolates are not clinically significant, but a recent study in the United States showed that the number of deaths from disease due to NTM was increasing.<sup>5</sup> It is important to assess the significance of the isolates by analyzing their specific clinical context in line with the recommendations of internationally recognized scientific societies, such as the American Thoracic Society (ATS), the British Thoracic Society (BTS) and the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR).<sup>16–18</sup>

Some diseases are often listed among the risk factors for mycobacterial infection: chronic obstructive pulmonary disease (COPD), pneumoconiosis, bronchiectasis, previous tuberculosis, post-radiotherapy fibrosis, chronic pulmonary aspiration (esophageal disease), cystic fibrosis, immune deficiency, HIV infection, alcoholism, cancer (lung or other sites), and diabetes mellitus. However, it should be noted that a high percentage of patients present no risk factors.<sup>2,5,16</sup>

The aim of this study was to determine the number and diversity of NTM species isolated in our region and their distribution according to the source of the sample, and the age and gender of the patient. Clinically significant isolates were also analyzed in detail.

## Methodology

This was a prospective study that included all mycobacteria isolated in Asturias (Spain) during the period 2005–2012. Isolates came from the 8 public hospitals in the region (mean population of 1,079,626 inhabitants) that systematically submit the isolated strains to the Regional Mycobacteria Reference Unit for identification and/or sensitivity testing.




Fig. 1. MTB and NTM isolates, 2005–2012.

Protocols following internationally accepted guidelines (American Society for Microbiology [ASM])<sup>19</sup> were used for the initial processing of the clinical samples.

The commercially available preparation BBL MycoPrep<sup>®</sup> (Specimen Digestion/Decontamination Kit, Becton-Dickinson) was used for the pretreatment digestion-decontamination phase.

Solid culture media (Löwenstein-Jensen) and liquid media with automated reading systems (BACTEC<sup>™</sup> MGIT<sup>™</sup> 960 [*Mycobacterial Growth Indicator Tube*] and/or Bact/ALERT<sup>®</sup> MP), were used for culture, according to the methodology of each hospital.

Species level identification was carried out using off-the-shelf techniques combining PCR and reverse hybridization (INNO-LiPA<sup>®</sup> Mycobacteria V2 and GENOTYPE<sup>®</sup> Mycobacterium CM/AS) and proprietary techniques (PRA<sup>20</sup> 16S-23S rRNA<sup>21</sup>) combining PCR-RFLP. Sequencing was not required in any of the clinically significant cases.

The criteria listed in the ATS/IDSA 2007 guidelines<sup>16</sup> were used to define a case as clinically significant. For statistical analysis of the data, 2×2 contingency tables were used to verify the independence of dichotomous variables, applying the Fisher's exact test. A value of  $P < 0.05$  was considered statistically significant.

## Results

During the study period, 3,284 mycobacteria isolated from 37,041 clinical samples were identified: 1,499 (45.7%) were *M. tuberculosis* complex (MTB) and 1,785 (54.3%) were NTM. Fig. 1 shows changes in the number of isolates by mycobacteria groups over the 8-year period of analysis; a growing trend for NTM and a waning trend for MTB can be observed.

In total, 1,785 NTM isolates were obtained from samples from 1,240 patients; 898 were men (72.4%) and 342 were women (27.6%). Mean patient age was 65 years (66.6 for men and 63.6 for women).




Fig. 2. Clinically significant cases in women and men, by age range.

Table 1  
NTM Isolates According to Source of Sample.

Source of Sample	Isolates (%)	Total Patients (%)	CS Isolates (%)
<i>Pulmonary</i>			
Sputum	1524 (85.3)	1026 (82.7)	148 (69.8)
BAS	93 (5.2)	76 (6)	10 (4.7)
BAL	8 (0.5)	8 (0.7)	4 (2)
Biopsy	7 (0.4)	6 (0.5)	3 (1.4)
<i>Extrapulmonary</i>			
Urine	39 (2.2)	31 (2.5)	10 (4.7)
Exudate	12 (0.7)	6 (0.5)	5 (2.4)
Skin biopsy	8 (0.5)	8 (0.7)	6 (2.8)
Lymph node	7 (0.4)	7 (0.6)	7 (3.3)
Stool	6 (0.3)	3 (0.2)	2 (0.9)
<i>Strains without specified source</i>	81 (4.5)	69 (5.6)	17 (8)
<b>Total</b>	<b>1785</b>	<b>1240</b>	<b>212</b>

BAL: bronchoalveolar lavage; BAS: bronchial aspirate; CS: clinically significant.

Overall, more isolates were obtained from men than from women ( $P < 0.001$ ). A total of 43.5% of the isolates were obtained in the first 4 years of the study (2005–2008). The greatest differences in isolation rates between men and women were recorded in the same period, while in the next 4-year period (2009–2012) the differences leveled out, until the last year when rates became equal (Fig. 2). NTM isolates from 212 patients were associated with clinically significant disease (17.1% of all patients in whom NTM were isolated), while the others were classified as colonization.

NTM isolates were obtained mainly from the respiratory tract (91.4%), 4% from various extrapulmonary sites, and in 4.5% of the cases the strains were sent to our laboratory without specifying the origin of the clinical sample (Table 1).

Sputum was the most common respiratory sample, followed by bronchial aspirate (BAS), bronchoalveolar lavage (BAL), and lung biopsy (Table 1). Clinically significant NTM in respiratory samples were more frequently isolated from lung biopsies (42.8%) and BAL (50%). The lowest percentage was recorded in sputum (9.5%).

Most isolates obtained from extrapulmonary samples were from urine, followed by exudate/abscess, skin biopsy, lymph node biopsy, and stool. NTM isolates in extrapulmonary samples were clinically significant in 100% of lymph node biopsies, 75% of skin biopsies, 41.6% of exudate/abscesses, 33.3% of stool samples, and 25.6% of urine samples.

The most frequently isolated species were *M. gordonae* (26.1%), *M. MAC* (15.3%), *M. fortuitum* (14.8%), *M. kansasii* (9.5%), *M. xenopi* (6.0%), *M. chelonae* (5.8%) and *M. abscessus* (4.2%). Overall, these accounted for 81.8% of the total number of isolates. Table 2 shows the rates of isolation of the different species of NTM per patient,

and their distribution by sex, in clinically significant cases. *M. gordonae* was the most frequently isolated species in our setting, but did not cause disease in any case. *M. kansasii* and *M. avium* were the two species of NTM most commonly associated with disease (33.5 and 21.2% of cases, respectively). Differences were found between the species isolated from men and from women. Among men, *M. kansasii* (25.9%), *M. avium* (13.7%), *M. fortuitum* (5.2%), *M. xenopi* (3.3%) and *M. chelonae* (3.3%) were the most frequent. In women, the most common species were *M. avium* (7.5%), *M. kansasii* (7.5%), *M. chelonae* (6.5%), *M. fortuitum* (3.3%) and *M. abscessus* (1.9%). In the case of *M. kansasii*, the difference in the number of isolates between women and men was statistically significant ( $P < 0.01$ ).

When the data were analyzed by sex and age range (Fig. 3), the largest number of NTM isolates occurred in patients older than 70 years of age, mainly men, while the incidence in younger patients was higher in women, particularly under the age of 30 ( $P = 0.01$ ). With regard to the correlation between the species isolated and the age range, we found that *M. kansasii*, *M. avium*, *MAC* and *M. abscessus* were isolated in younger women, while in men in that age range, only *M. avium* was isolated. *M. intracellulare*, in contrast, was only isolated in women over 50 years of age, reaching maximum values in patients older than 70 years. The largest number of isolates of *M. intracellulare* and *MAC* occurred in men over the age of 60 years. In the case of *M. xenopi*, all isolates, with the exception of 1, were obtained from men. In contrast, twice as many *M. chelonae* isolates were obtained from women than from men.

With regard to the source of the sample (Table 3), practically all NTM were isolated from lung samples (91.42%), mostly in sputum, except for *M. marinum* and *M. genavense*, isolated from a skin biopsy and a lymph node biopsy, respectively. In patients younger than 20 years, mycobacteria were isolated mainly from extrapulmonary sites.

Risk factors and comorbidities among the 212 patients with clinically significant NTM isolates, classified by NTM species, are shown in Table 4. Interestingly, 166 patients (78.3%) had comorbidities, frequently with 2 or more risk factors. With the exception of *M. abscessus*, a species frequently associated with cystic fibrosis/bronchiectasis, no association was found between any specific underlying disease and the type of NTM identified.

In most cases, treatment was initiated in line with the recommendations published in the standard clinical guidelines (Table 5). Mean treatment duration was 12 months (range 6–36 months). Three percent of patients did not receive treatment.

With regard to clinical progress, 50 patients (23.6%) died (43 men and 7 women; mean age, 73 years), primarily due to causes associated with their underlying pathology. It is also noteworthy that despite antimycobacterial treatment, NTM was persistently isolated in 5.1% of patients.

## Discussion

Over the 8-year study period in Asturias, we observed a 35% increase in NTM isolates compared to a 21% reduction in MTB cases over the same period. Similar results have been reported in other recent studies.<sup>7,9,11,12</sup>

This same trend has been observed in most industrialized countries, although the incidence rates vary widely depending on the country concerned: 4.8–5.6 cases per 100,000 inhabitants between 2007 and 2012, respectively, in Oregon<sup>6</sup>; 2.06–2.71 cases per 100,000 inhabitants in Scotland between 2000 and 2010<sup>7</sup>; rates in England, Wales and Northern Ireland rose from 0.9 to 2.9 isolates per 100,000 inhabitants between 1995 and 2006,<sup>9</sup> and in Queensland (Australia), rates increased from 2.2 (1999) to 3.2 (2005) cases per 100,000 inhabitants.<sup>10</sup>

**Table 2**  
Isolates Identified by Species, Patient Numbers and Sex Distribution in Clinically Significant Cases.

Species	Isolates			CS Cases (by Sex)						M:F
	n	%	Patients	n	%	♂	%	♀	%	
<i>M. gordonae</i>	466	26.1	371	–	–	–	–	–	–	–
MAC	273	15.3	143	71	33.5	40	18.9	31	14.7	1.29
<i>M. avium</i>	131	7.3	68	45	21.2	29	13.7	16	7.6	1.81
<i>M. intracellulare</i>	101	5.6	44	15	7.1	7	3.3	8	3.8	0.88
<i>M. avium</i> complex	42	2.4	31	11	5.2	4	1.9	7	3.3	0.57
<i>M. fortuitum</i>	265	14.8	211	18	8.5	11	5.2	7	3.3	1.57
<i>M. kansasii</i>	169	9.5	77	71	33.5	55	25.9	16	7.6	3.44
<i>M. xenopi</i>	108	6.0	69	8	3.8	7	3.3	1	0.5	7.00
<i>M. chelonae</i>	104	5.8	81	21	9.9	7	3.3	14	6.6	0.50
<i>M. abscessus</i>	75	4.2	9	5	2.3	1	0.5	4	1.9	0.25
<i>M. peregrinum</i>	47	2.6	41	2	0.9	1	0.5	1	0.5	1.00
<i>M. mucogenicum</i>	44	2.5	38	1	0.5	1	0.5	–	–	–
<i>M. lentiflavum</i>	43	2.4	32	1	0.5	–	–	1	0.5	–
<i>M. nonchromogenicum</i>	20	1.1	17	2	0.9	2	0.5	–	–	–
<i>M. marinum</i>	1	0.1	1	1	0.5	–	–	1	0.5	–
<i>M. asiaticum</i>	1	0.1	1	1	0.5	–	–	1	0.5	–
<i>M. genavense</i>	1	0.1	1	1	0.5	–	–	1	0.5	–
Others <sup>a</sup>	167	9.4	148	9	4.2	8	3.8	1	0.5	–
Total	1785	100	1240	212	100	133	62.4	79	37.6	

CS: clinically significant.

<sup>a</sup> "Others" includes species that could not be identified at the species level (61), isolation of 2 species simultaneously (31), and identified species occurring at a very low frequency (75), which in no case were considered pathogenic: *M. smegmatis* (9), *M. simiae* (7), *M. terrae* (7), *M. celatum* (7), *M. goodii* (6), *M. chitae* (5), *M. malmoense* (4), *M. neoaurum* (3), *M. scrofulaceum* (3), *M. triviale* (3), *M. szulgai* (3), *M. interjectum* (3), *M. confluentis* (2), *M. flavescens* (2), *M. phlei* (2), *M. thermoresistibile* (2), *M. immunogenum* (1), *M. gadium* (1), *M. gilvum* (1), *M. heckeshornense* (1), *M. parafortuitum* (1), *M. parascrofulaceum* (1) and *M. pulveris* (1).

**Table 3**  
NTM Species by Sample Type.

Species	NTM by Sample Type (Clinically Significant Isolates)										
	n	Pulmonary				Extrapulmonary					
		Sputum	BAS	BAL	Biopsy	Urine	Exudate	Skin	Lymph node	Stool	Strains
<i>M. gordonae</i>	466	415	30	3	1	10	1	1	–	1	4
MAC	274 (71)	226 (49)	13 (3)	2 (2)	–	7 (2)	2 (1)	–	4 (4)	5 (2)	15 (8)
<i>M. avium</i>	131 (45)	102 (31)	10 (3)	1 (1)	–	4 (1)	2 (1)	–	2 (2)	5 (2)	5 (4)
<i>M. intracellulare</i>	101 (15)	87 (10)	3	1 (1)	–	–	–	–	1 (1)	–	9 (3)
<i>M. avium</i> complex	42 (11)	37 (8)	–	–	–	3 (1)	–	–	1 (1)	–	1 (1)
<i>M. fortuitum</i>	265 (18)	227 (11)	10	1	–	7 (3)	6 (4)	–	–	–	14
<i>M. kansasii</i>	169 (71)	142 (53)	12 (7)	1 (1)	4 (3)	–	–	–	–	–	10 (7)
<i>M. xenopi</i>	108 (8)	99 (7)	4	–	1	–	1 (1)	–	–	–	3
<i>M. chelonae</i>	104 (21)	81 (11)	–	–	–	8 (4)	2	3 (3)	1 (1)	–	9 (2)
<i>M. abscessus</i>	75 (5)	72 (5)	2	–	–	–	–	–	1 (1)	–	–
<i>M. peregrinum</i>	47 (2)	43 (1)	1	–	–	2 (1)	–	–	–	–	1
<i>M. mucogenicum</i>	44 (1)	34	1	–	–	–	–	3 (1)	–	–	6
<i>M. lentiflavum</i>	43 (1)	32 (1)	8	–	–	1	–	–	–	–	2
<i>M. nonchromogenicum</i>	20 (2)	16 (1)	–	–	–	–	–	–	–	–	4 (1)
<i>M. marinum</i>	1 (1)	–	–	–	–	–	–	1 (1)	–	–	–
<i>M. asiaticum</i>	1 (1)	1 (1)	–	–	–	–	–	–	–	–	–
<i>M. genavense</i>	1 (1)	–	–	–	–	–	–	–	1 (1)	–	–
Others <sup>a</sup>	167 (9)	136 (7)	12	1 (1)	1	4	–	–	–	–	13 (1)
Total	1785 (212)	1524 (146)	93 (10)	8 (4)	7 (3)	39 (10)	12 (6)	8 (5)	7 (7)	6 (2)	81 (19)


BAL: bronchoalveolar lavage; BA: bronchial aspirate; CS: clinically significant.

<sup>a</sup> "Others" includes species that could not be identified at the species level (61), isolation of 2 species simultaneously (31), and identified species occurring at a very low frequency (75), which in no case were considered pathogenic: *M. smegmatis* (9), *M. simiae* (7), *M. terrae* (7), *M. celatum* (7), *M. goodii* (6), *M. chitae* (5), *M. malmoense* (4), *M. neoaurum* (3), *M. scrofulaceum* (3), *M. triviale* (3), *M. szulgai* (3), *M. interjectum* (3), *M. confluentis* (2), *M. flavescens* (2), *M. phlei* (2), *M. thermoresistibile* (2), *M. immunogenum* (1), *M. gadium* (1), *M. gilvum* (1), *M. heckeshornense* (1), *M. parafortuitum* (1), *M. parascrofulaceum* (1) and *M. pulveris* (1).

The increase in Asturias has been gradual, rising from a total of 106 isolates at the beginning of our study to 164 isolates obtained in the last year. With regard to isolation rates, 9.82 isolates per 100,000 inhabitants were recorded in 2005, a figure that in 2012 rose to 15.19. Clinically significant cases fell slightly, from 2.31 cases per 100,000 in 2005 to 2.03 in 2012, with a maximum number of 3.52 cases recorded in 2008. The mean isolation rate in the 8-year study period was 2.46 episodes per 100,000 inhabitants; very similar rates were obtained in Scotland during the same period<sup>7</sup> and

in New York,<sup>8</sup> but the numbers recorded in Oregon were slightly higher.<sup>6</sup>

With regard to the gender distribution of the NTM isolates, three times as many isolates were obtained in men than women. The differences were more marked during the early years of the study, but tended to level out over time; other authors have also made the same observation.<sup>7,10,12</sup> Similar findings were reported in clinically significant cases. However, series have also been published in which more NTM were isolated from women.<sup>13</sup>



**Fig. 3.** (A, B) Distribution of NTM species in men and women according to age range in cases with clinically significant isolates.

**Table 4**  
Comorbidity Reported in 212 Patients With Clinically Significant Isolates of NTM.

Concomitant Disease	Clinically Significant Isolates									Total n=212
	<i>M. kansasii</i> n=71	<i>M. avium</i> n=45	MAC n=11	<i>M. intracellulare</i> n=15	<i>M. chelonae</i> n=21	<i>M. fortuitum</i> n=18	<i>M. xenopi</i> n=8	<i>M. abscessus</i> n=5	Other NTM n=18	
Previous tuberculosis	20	5	3	3	3	5	2	2	2	45
Lung cancer	8	2	0	5	0	3	0	0	2	20
Other cancer	6	3	2	3	2	6	2	0	1	25
COPD	24	9	2	3	3	8	5	0	7	61
BC	31	9	0	3	2	3	3	5	3	59
Emphysema	13	3	2	2	2	6	2	0	3	33
HIV positive	2	5	4	0	0	0	2	0	1	14
DM	2	6	0	2	3	2	2	0	6	23
Transplant	3	0	0	0	6	0	0	0	4	13
CF	2	0	0	0	0	0	0	3	2	7
Total comorbidities	106	42	13	21	21	33	18	10	31	300
No risk factors	12	10	8	2	0	12	0	0	2	46

BC: bronchiectasis; CF: cystic fibrosis; COPD: chronic obstructive pulmonary disease; DM, diabetes mellitus; HIV: human immunodeficiency virus.



**Table 5**  
Treatment Regimens Administered to Patients With Mycobacterial Infection.

NTM <sup>a</sup>	Treatment	Duration
<i>M. kansasii</i>	R+H+EMB (+CL+LZ)	≥12 months
<i>M. avium</i>	R+CL+EMB (+H)	6–12 months
MAC	R+EMB (+CL+H)	≥12 months
<i>M. intracellulare</i>	R+CL+EMB (+RB+AZ+H)	12–36 months
<i>M. chelonae</i>	CL+LF+DX (+R+H)	6 months
<i>M. fortuitum</i>	R+H (+EMB+CL+LF+CP)	6–24 months
<i>M. xenopi</i>	R+H (+CL/EMB)	6–24 months
<i>M. abscessus</i>	CL+AK (+CP+CF)	≥12 months
<i>M. marinum</i>	R+CL+EMB	6 months
<i>M. genavense</i>	R+CL+EMB	6 months

AK: amikacin; AZ: azithromycin; CF: cefoxitin; CL: clarithromycin; CP: ciprofloxacin; DX: doxycycline; EMB: ethambutol; H: isoniazid; LF: levofloxacin; R: rifampicin; RB: rifabutin.

<sup>a</sup> NTM with clinically significant isolates not listed in the table (16 cases); 6 were not treated, and of the remaining 10: *M. asiaticum* (1), *M. lentiflavum* (1), *M. mucogenicum* (1), *M. peregrinum* (2), *M. immunogenum* (1), *M. malmoense* (1), *M. szulgai* (2), *M. interjectum* (1), although the treatment regimen depended on the species, the most frequent combination being quinolone+macrolide with/without ethambutol and/or rifampin.

With regard to age, the highest number of isolates (approximately 80%) were obtained from the clinical samples of individuals older than 50 years, and, in line with data from other recent studies, greater numbers of species were isolated from patients over 70 years of age.<sup>7,9,13–15</sup>

The most frequently isolated species of NTM was *M. gordonae*, the second most frequently isolated mycobacteria worldwide,<sup>11</sup> but in none of the cases was it considered pathogenic. The MAC complex, which is the most frequently isolated NTM on a worldwide basis, came in second (15.29%). In another study performed in Spain between 1976 and 1996,<sup>22</sup> high percentages of MAC were also obtained in practically all regions except the Canary Islands, although the impact of HIV disease at that time must be taken into account. In Asturias, *M. fortuitum* and *M. kansasii* were ranked third and fourth, respectively, while on a global level they are ranked fourth and sixth. In Europe, Slovakia, Poland and the United Kingdom<sup>11</sup> recorded the highest rates of *M. kansasii* isolates. With regard to geographical distribution, in Spain,<sup>22</sup> *M. kansasii* has been described mainly in the southern regions, particularly the Community of Valencia, and also in northern regions, such as the Basque Country, where a study performed in Bilbao in 2005<sup>23</sup> revealed high rates of isolates of this species, while in the border provinces, isolates of this species were virtually non-existent.

With regard to the isolate/pathogenicity ratio found in our series, MAC and *M. kansasii* were the species that most often caused disease, accounting together for 67% of all cases (142 patients). *M. kansasii* was predominant in men, the difference being statistically significant ( $P<0.01$ ). Cases caused by *M. xenopi* and *M. abscessus* were similar to those of other studies.<sup>7,12</sup> *M. marinum*, *M. asiaticum* and *M. genavense* were all isolated once only, and all 3 were considered clinically significant.

Comorbidities were identified in 166 patients (78.3%), most commonly in cases caused by *M. xenopi* and *M. abscessus*; in contrast, no risk factors were identified in 46 patients (21.7%), similar to findings published in New York,<sup>8</sup> while *M. kansasii* was the NTM most frequently isolated in cases without comorbidities.<sup>24</sup> In transplant patients, *M. chelonae* and *M. kansasii* were the most common NTM, unlike other studies,<sup>5</sup> in which the most common were MAC and *M. abscessus*.

With respect to treatment, 97% of patients received a 3-drug combination, and the mean treatment duration was 12 months. NTM persisted in 5.1% of patients, despite antimycobacterial treatment. As this study pools patients diagnosed in 8 different hospitals, treatment regimens were often heterogeneous, particularly with

regard to treatment duration and inclusion or exclusion of certain drugs recommended in the literature.<sup>25</sup>

In conclusion, we can confirm that our region has also seen a marked increase in the number of NTM isolates. Both isolation of NTM and clinically significant cases were more common in men. Only 17.1% of NTM isolates caused disease, the most frequent in these cases being MAC and *M. kansasii*.

Finally, it should be noted that, paradoxically, despite the increase in the number of NTM isolates registered in our region, the number of cases in which the isolate was considered clinically significant did not increase, but rather fell in the later years of our study, mainly due to the increase of NTM isolates with low pathogenic potential.

## Authorship

Juan José Palacios Gutiérrez, head of the HUCA Regional Mycobacteria Reference Unit directed the study and was responsible for the final review and correction of the manuscript.

Susana Martínez González was responsible for data collection, analysis and interpretation, and preparation of the manuscript.

Arantza Cano Cortés and Luis Alfonso Sota Yoldi participated in the compilation of clinical data and in the critical review of the article.

José María García García acted as a study consultant and participated in the critical review of the article.

Luz María Alba Álvarez was responsible for the literature review.

The SESPA Microbiology Laboratory Network was responsible for isolation of strains submitted by the HUCA Regional Mycobacteria Reference Unit.

## Conflict of Interests

The authors state that they have no conflict of interests.

## Acknowledgements

We thank Ángela Menéndez González, Ángeles Díaz Escalada, Macarena Álvarez Fernández, M.J. Rodríguez and Zulima Velasco for their help and support at all times in the performing the technical aspects of this work, without which we could not have completed this project.

## References

- Alcaide Fernández de Vega F, Esteban Moreno J, González Martín J, Palacios Gutiérrez JJ. Métodos de determinación de sensibilidad a los antimicrobianos en micobacterias. In: Cercenado Mansilla E, Cantón Moreno R, editors. Procedimientos en Microbiología Clínica. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC); 2016. Cap. 56.
- Medina Cruz MV, Sauret Valet J, Caminero Luna JA. Enfermedades producidas por micobacterias ambientales. Med Clin. 1999;113:621–30.
- Jenkins PA. The laboratory diagnosis of mycobacterial disease. Commun Dis Rep CDR Rev. 1992;2:R101–10.
- Watterson SA, Drobniewski FA. Modern laboratory diagnosis of mycobacterial infections. J Clin Pathol. 2000;53:727–32.
- Mirsaeidi M, Farshidpour M, Allen MB, Ebrahimi G, Falkinham JO. Highlight on advances in nontuberculous mycobacterial disease in North America. BioMed Res Int. 2014. <http://dx.doi.org/10.1155/2014/919474>
- Henkle E, Hedberg K, Schafer S, Novosad S, Winthrop KL. Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012. Annals ATS. 2015;12:642–7.
- Russell CD, Claxton P, Doig C, Seagar AL, Rayner A, Laurenson IF. Non-tuberculous mycobacteria: a retrospective review of Scottish isolates from 2000 to 2010. Thorax. 2013;69:1–3.
- Bodle EE, Cunningham JA, della-Latta P, Schluger NW, Saiman L. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis. 2008;14:390–6.
- Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995–2006. BMC Publ Health. 2010;10:612.

10. Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. *Emerg Infect Dis*. 2010;16:1576–83.
11. Hoefsloot W, van Ingen J, Andrejak C, Ångeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. *Eur Respir J*. 2013;42:1604–13.
12. Streit E, Millet J, Rastogi N. Nontuberculous mycobacteria in Guadeloupe, Martinique, and French Guiana from 1994 to 2012. *Tuberc Res Treat*. 2013;2013:472041.
13. Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. *Clin Infect Dis*. 2009;49:e124–9.
14. Kim JK, Rheem I. Identification and distribution of nontuberculous mycobacteria from 2005 to 2011 in Cheonan, Korea. *Tuberc Respir Dis*. 2013;74:215–21.
15. Lee MY, Lee T, Kim MH, Byun SS, Ko MK, Hong JM, et al. Regional differences of nontuberculous mycobacteria species in Ulsan, Korea. *J Thorac Dis*. 2014;6:965–70.
16. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med*. 2007;175:367–416.
17. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. *Thorax*. 2000;55:210–8.
18. Ruiz Manzano J, Blanquer R, Calpe JL, Caminero JA, Caylá J, Domínguez JA, et al. Diagnóstico y tratamiento de la tuberculosis. *Arch Bronconeumol*. 2008;44:551–66.
19. Pfyffer GE, Palicova F. Mycobacterium: general characteristics, laboratory detection and staining procedures. Capítulo 28. In: Versalovic L, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, editors. *Manual of clinical microbiology*. 10th ed. American Society for Microbiology (ASM); 2011. p. 472–502.
20. Telenti A, Marchesi F, Balz M, Bally F, Botrger EC, Bodmer T. Rapid identification of Mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. *J Clin Microbiol*. 1993;31:175–8.
21. Roth A, Fischer M, Hamid ME, Michalke S, Ludwig W, Mauch H. Differentiation of phylogenetically related slowly growing mycobacteria based on 16S-23S rRNA gene internal transcribed spacer sequences. *J Clin Microbiol*. 1998;36:139–47.
22. Casabona NM, Roselló J. Micobacterias ambientales en España: aislamientos en el período 1976–1996. *Med Clin (Barc)*. 2000;115:663–70.
23. Leal MV, Gaafar A, Unzaga MJ, Crespo JA, Cisterna R, García F. Estudio clinicoepidemiológico de la enfermedad por *Mycobacterium kansasii* en el área urbana de Bilbao. *Arch Bronconeumol*. 2005;41:189–96.
24. Falkinhan JO. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. *J Appl Microbiol*. 2009;356–67.
25. García García JM, Palacios Gutiérrez JJ, Sánchez Antuña AA. Infecciones respiratorias por micobacterias ambientales. *Arch Bronconeumol*. 2005;41:206–19.